Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Keyphrases

• Rivaroxaban 100%
• Patients with Heart Failure 100%
• Coronary Disease 100%
• Sinus Rhythm 100%
• Placebo 57%
• Hazard Ratio 42%
• Coronary Artery Disease 42%
• Chronic Heart Failure 42%
• 95% Confidence Interval 42%
• Myocardial Infarction 28%
• Atrial Fibrillation 28%
• Twice Daily 28%
• Safety Outcomes 28%
• Non-associated 14%
• No Significant Difference 14%
• Placebo Groups 14%
• Plasma Concentration 14%
• Heart Failure 14%
• Mortality Rate 14%
• Thrombin 14%
• Factor Xa Inhibitors 14%
• Bleeding 14%
• Low Dose Rate 14%
• All-cause Mortality 14%
• Left Ventricular Ejection Fraction 14%
• Poor Prognosis 14%
• Natriuretic Peptides 14%
• Fatal Bleeding 14%
• Improved Outcomes 14%
• Double-blind Trial 14%
• Related Pathway 14%
• Worsening Heart Failure 14%
• Thrombin Generation 14%
• Permanent Disability 14%
• Reduced Left Ventricular Ejection Fraction 14%
• Efficacy Outcomes 14%

Medicine and Dentistry

• Rivaroxaban 100%
• Coronary Artery Disease 100%
• Ischemic Heart Disease 100%
• Congestive Heart Failure 100%
• Sinus Rhythm 100%
• Placebo 71%
• Hazard Ratio 42%
• Myocardial Infarction 28%
• Bleeding 28%
• Apoplexy 28%
• Thrombin 28%
• Atrial Fibrillation 28%
• Heart Left Ventricle Ejection Fraction 28%
• Natriuretic Factor 14%
• Blood Clotting Factor 10a Inhibitor 14%
• All Cause Mortality 14%
• Median Follow Up 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Ischemic Heart Disease 100%
• Rivaroxaban 100%
• Coronary Artery Disease 100%
• Congestive Heart Failure 100%
• Placebo 71%
• Heart Infarction 28%
• Atrial Fibrillation 28%
• Bleeding 28%
• Thrombin 28%
• Cerebrovascular Accident 28%
• Natriuretic Factor 14%
• Blood Clotting Factor 10a Inhibitor 14%
• All Cause Mortality 14%